Stoke Therapeutics, Inc. STOK Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s free cash flow?
- Stoke Therapeutics, Inc. (STOK) reported free cash flow of -$60.94M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s free cash flow changed year-over-year?
- Stoke Therapeutics, Inc.'s free cash flow decreased by 146.3% year-over-year, from $131.68M to -$60.94M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s free cash flow?
- Over 3 years (2021 to 2024), Stoke Therapeutics, Inc.'s free cash flow has grown at a 8.5% compound annual growth rate (CAGR), from -$68.11M to -$87.05M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.